Holen Sie sich die Stockscreener-App
7.08
3.01%
-0.22
Handel nachbörslich:
7.09
0.010
+0.14%
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio (IBRX) Faces FDA Warning, BTIG Stays Positive - Insider Monkey
FDA warns company over cancer drug claims - Santa Clarita Valley Signal
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio And 2 Insider Picks For Promising Growth - simplywall.st
FDA issues warning letter to ImmunityBio over misleading promotion of NAI - Urology Times
FDA Flags Anktiva Claims While ImmunityBio Pushes Regulatory Fixes - Benzinga
ImmunityBio Addresses FDA Concerns on Promotional Materials, Enhances Compliance Measures for ANKTIVA® 1 - Minichart
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
ImmunityBio Addresses FDA Warning on ANKTIVA Promotion - TipRanks
ImmunityBio responds to FDA promotional compliance concerns - Investing.com
ImmunityBio (IBRX) Stock Gains 3% Following FDA Compliance Response on Anktiva Marketing - blockonomi.com
ImmunityBio submits response to FDA OPDP, removes podcast and strengthens promotional compliance - TradingView
ImmunityBio responds to FDA promotional compliance concerns By Investing.com - Investing.com India
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - stocktitan.net
ImmunityBio (IBRX) Stock Climbs 3% After Firing Back at FDA Over Anktiva Ad Concerns - CoinCentral
ImmunityBio stock rises after FDA compliance response By Investing.com - Investing.com Canada
ImmunityBio addresses FDA correspondence and reaffirms commitment to advertising compliance - marketscreener.com
Immunitybio Addresses FDA Correspondence And Reaffirms Commitment To Advertising Compliance - TradingView
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance - businesswire.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald
Securing Non-Dilutive Funding to Support Immunotherapy Platform Growth – ImmunityBio - Oncodaily
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Downgrade) - Seeking Alpha
IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio - gurufocus.com
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up - TipRanks
IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Morningstar
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - Sahm
Investors with Substantial Losses in ImmunityBio (IBRX) Have Opportunity to Lead Class Action Lawsuit - National Today
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - Carroll County Mirror-Democrat
When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio - Medical Marketing and Media
ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline - PR Newswire
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jim Cramer on ImmunityBio: "I would encourage you to own it, provided you don’t own any other spec" - MSN
ImmunityBio Sued for Securities Law Violations - National Today
ImmunityBio Faces Investor Lawsuit Over Cancer Drug Claims - AD HOC NEWS
ImmunityBio (IBRX) insider converts $25M note into 4.6M shares - stocktitan.net
IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire Inc.
ImmunityBio (NASDAQ:IBRX) Trading 2.2% HigherTime to Buy? - MarketBeat
ImmunityBio: No Need To Rush Into Buying TodayWhy I'm Downgrading To Hold (NASDAQ:IBRX) - Seeking Alpha
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces - GlobeNewswire
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of ... - Bluefield Daily Telegraph
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — Hagens Berman - Morningstar
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm - Morningstar
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter - MSN
ImmunityBio (IBRX) Rallies 15% as Firm Raises $100M For Global Expansion - Insider Monkey
IBRX Stock Notches Strongest Quarter Ever — But These 2 Smaller Biotech Plays Ran Even Hotter - Stocktwits
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - Bitget
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):